Synthesis and structure-activity relationships of novel arylalkyl 4- benzyl piperazine derivatives as σ site selective ligands

European Journal of Medicinal Chemistry

Volumn 35, Issue 1, 2000, Pages 107-121

  Younes, Salomé ^a   Labssita, Youssef ^a   Baziard Mouysset, Geneviève ^a   Payard, Marc ^a   Rettori, Marie Claire ^b   Renard, Pierre ^b   Pfeiffer, Bruno ^b   Caignard, Daniel Henri ^b  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Benzylpiperazine; Inflammation; Psychosis; Sigma ligand

Indexed keywords

1 (2 NAPHTHYLMETHYL) 4 BENZYLPIPERAZINE; ANTIINFLAMMATORY AGENT; DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; DRUG ACTIVITY; DRUG BINDING; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; INFLAMMATION; NONHUMAN; PSYCHOSIS; RAT; STRUCTURE ACTIVITY RELATION;

EID: 0034104608     PISSN: 02235234     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0223-5234(00)00113-6     Document Type: Article

References (15)

1. Baziard-Mouysset G., Younes S., Labssita Y., Payard M., Caignard D.H., Rettori M.C., et al. Eur. J. Med. Chem. 33:1998;339-347.
2. Carr D.J., De Costa B.R., Radesca L., Radesca T., Blalock J.F. J. Neuroimmunol. 35:1991;153-166.
3. Derocq J.M., Bourrie B., Segui M., Lefur G., Castellas P. J. Pharmacol. Exp. Ther. 272:1995;224-230.
4. Karbon E.W., Naper K., Pontecorvo M.J. Eur. J. Pharmacol. 193:1991;21-27.
5. De Haven-Hudkins D.L., Fleissner L.C., Ford-Rice F.Y. Eur. J. Pharmacol. 227:1992;371-378.
6. Weber E., Sonders M., Quarum M., McLean S., Pou S., Keana J.F.W. Proc. Natl. Acad. Sci. USA. 83:1986;8784-8788.
7. Hoyer D., Engel G., Kalkman H.O. Eur. J. Pharmacol. 118:1985;13-23.
8. Kohier L., Hall H., Ogren S.V., Gawell L. Biochem. Pharmacol. 34:1985;2251-2259.
9. Costall B., Marsden C.D., Naylor R.J., Pycock C.J. Brain Research. 123:1977;89-111.
10. Monnet F.P., Debonnel G., De Montigny C. J. Pharmacol. Exp. Ther. 261:1992;123-130.
11. Monnet F.P., Debonnel G., Junien J.L., De Montigny C. Eur. J. Pharmacol. 179:1990;441-445.
12. Haigler H.J., Aghajanian G.K. J. Pharmacol. Exp. Ther. 168:1974;688-699.
13. Bergeron R., Debonnel G., De Montigny C. Eur. J. Pharmacol. 240:1993;319-323.
14. Kandal E.R., Spencer W.A. J. Neurophysiol. 24:1961;243-259.
15. Winter C.A., Risiey E.A., Nuss G.W. Proc. Soc. Exp. Bio. M. 111:1962;544-547.